Hyperbaric oxygen treatment and toll-like receptor 5 in radioprotection of epithelial cells
PLOS One · 14.08.2026 · 21 (8) · e0356247
DOI: 10.1371/journal.pone.0356247 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 14.08.2026. Verfasst von Lana Sallam und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Epithelial Cells, Toll-Like Receptor 5, Hyperbaric Oxygenation, Radiation-Protective Agents. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stiftelsen Jubileumsklinikens Forskningsfond mot Cancer, Western County Council Clinical Research Foundation.
Abstract (Originalsprache)
Background
Irradiation of tumours in the pelvic area may lead to adverse effects such as vaginal fibrosis and dyspareunia. We investigated the radioprotective effects of hyperbaric oxygen (HBOT) and toll-like receptor 5 (TLR5) in epithelial cells. Methods and materials Endothelial cells (HUVEC), urothelial cells (UROtsa), and cervical epithelial cells (HeLa) were irradiated with 6 Gy and subsequently underwent HBOT. Cells were counted and qPCR was performed on HeLa for the expressions of TLR5, downstream signalling molecules, oxidative stress, and cytokines. The effects of the TLR5 agonist flagellin and the TLR5 antagonist TH1020 on radiation-induced cell death and oxidative stress were assessed.
Results
HBOT attenuated radiation-induced epithelial cell death. In HeLa, radiation reduced TLR5, TRIF, NRF2, HIF-α and catalase expression. HBOT reversed their expression. The TLR5 agonist flagellin protected against radiation-induced cell death in HeLa and the TLR5 antagonist TH1020 inhibited the radioprotective effects by flagellin.
Conclusions
HBOT antagonizes radiation-induced cell death and normalizes the expressions of antioxidants, TLR5 and connected downstream signalling transcripts. TLR5 signalling contributes to protection from radiation-induced epithelial cell death, which supports further exploration of combined HBOT-TLR5-targeted strategies for mucosal radioprotection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
- Department of Pharmacology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
- Department of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
- Department of Laboratory Medicine and Core Facilities, Institute of Biomedicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
- Department of Anesthesiology and Intensive Care Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
ORCID-Profile: Daniel Giglio
Förderung
- Stiftelsen Jubileumsklinikens Forskningsfond mot Cancer
- Western County Council Clinical Research Foundation
Zitieren
APA
Sallam, L., Rychlíková, L., Mölne, J., Bergo, M. O., Naluai, Å. T., Seeman-Lodding, H., Oscarsson, N., & Giglio, D. (2026). Hyperbaric oxygen treatment and toll-like receptor 5 in radioprotection of epithelial cells. PLOS One, 21(8), e0356247. https://doi.org/10.1371/journal.pone.0356247
Vancouver
Sallam L, Rychlíková L, Mölne J, Bergo MO, Naluai ÅT, Seeman-Lodding H, et al. Hyperbaric oxygen treatment and toll-like receptor 5 in radioprotection of epithelial cells. PLOS One. 2026;21(8):e0356247. doi:10.1371/journal.pone.0356247
BibTeX
@article{Sallam2026,
author = {Sallam, Lana and Rychlíková, Lucie and Mölne, Johan and Bergo, Martin O and Naluai, Åsa Torinsson and Seeman-Lodding, Helene and Oscarsson, Nicklas and Giglio, Daniel},
title = {Hyperbaric oxygen treatment and toll-like receptor 5 in radioprotection of epithelial cells},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {8},
pages = {e0356247},
doi = {10.1371/journal.pone.0356247}
}
EUVIMED